Description

COVID-19 drugs must be manufactured under good manufacturing practices (GMP) conditions. These conditions must be in line with the international requirements outlined in the International Council for Harmonization Q7A guideline and with applicable Health Canada's guidance.

Resources

Name	Format	Description	Link
Guidance for market authorization requirements for COVID-19 drugs: Quality and manufacturing requirements	HTML		https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/guidance-market-authorization-drugs/quality-manufacturing-requirements.html
Guidance for market authorization requirements for COVID-19 drugs: Quality and manufacturing requirements	HTML		https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/lignes-directrices-autorisations-mise-marche-medicaments/exigences-qualite-fabrication.html

Tags

Topics

Categories